kabutan

PhoenixBio Co.,Ltd.(6190) Summary

6190
TSE Growth
PhoenixBio Co.,Ltd.
447
JPY
-1
(-0.22%)
Mar 13, 3:30 pm JST
2.80
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
16.5
PBR
1.21
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
448 JPY 2.81 USD
Previous Close Mar 12
448 JPY 2.81 USD
High Mar 13, 1:20 pm
458 JPY 2.87 USD
Low Mar 13, 10:50 am
441 JPY 2.76 USD
Volume
11,100
Trading Value
5.00M JPY 0.03M USD
VWAP
449.78 JPY 2.82 USD
Minimum Trading Value
44,700 JPY 280 USD
Market Cap
1.82B JPY 0.01B USD
Number of Trades
57
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
304
1-Year High Oct 22, 2025
5,640
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 319,300
Feb 27, 2026 0 301,500
Feb 20, 2026 0 294,400
Feb 13, 2026 0 301,200
Feb 6, 2026 0 298,800
Company Profile
PhoenixBio Co., Ltd. is a biotech venture originating from Hiroshima University, specializing in the production of PXB mice with high human hepatocyte replacement rates and contract testing services.
Sector
Services
PhoenixBio, a biotech venture spun off from Hiroshima University, primarily focuses on providing contract testing services for drug development using PXB mice. PXB mice are chimeric mice with livers largely replaced by human hepatocytes, used for predicting human metabolism and researching hepatitis viruses. The company's main services include pharmacokinetic studies, safety tests, and efficacy evaluations for hepatitis drugs. Additionally, PhoenixBio sells fresh human hepatocytes (PXB-cells) obtained from PXB mice. These services play a crucial role in the preclinical stages of new drug development, supporting pharmaceutical companies in their drug discovery research.